TTOO - T2 Biosystems Inc Stock Price, Fair Value and News

2.75USD+0.03 (+1.10%)Market Closed

Market Summary

USD2.75+0.03

Market Closed

1.10%

TTOO Stock Price

View Fullscreen

TTOO RSI Chart

TTOO Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.3

Price/Sales (Trailing)

2.11

Price/Free Cashflow

-0.31

TTOO Price/Sales (Trailing)

TTOO Profitability

Return on Equity

-555.86%

Return on Assets

-143.91%

Free Cashflow Yield

-318.81%

TTOO Fundamentals

TTOO Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

-69.38%

Rev. Growth (Qtr)

14.06%

TTOO Earnings

Earnings (TTM)

-50.1M

Earnings Growth (Yr)

-2.39%

Earnings Growth (Qtr)

32.97%

Breaking Down TTOO Revenue

Last 7 days

-6.5%

Last 30 days

-7.7%

Last 90 days

-33.1%

Trailing 12 Months

693.9%

How does TTOO drawdown profile look like?

TTOO Financial Health

Current Ratio

0.45

TTOO Investor Care

Shares Dilution (1Y)

2606.31%

Diluted EPS (TTM)

-80.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	17.1M	13.2M	11.0M	7.2M
2022	28.3M	27.6M	23.8M	22.3M
2021	22.5M	26.7M	28.9M	28.1M
2020	9.1M	9.8M	13.4M	18.1M
2019	10.0M	7.8M	7.1M	8.3M
2018	6.0M	9.0M	10.4M	10.5M
2017	3.9M	3.9M	3.9M	4.7M
2016	3.7M	4.1M	4.2M	4.1M
2015	454.0K	927.0K	1.9M	2.8M
2014	0	0	0	385.0K
2013	0	101.3K	183.7K	266.0K
2012	0	0	0	19.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of T2 Biosystems Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	cr group l.p.	acquired	-	-	390,142	-
Apr 12, 2024	cr group l.p.	acquired	-	-	1,647,320	-
Apr 12, 2024	cr group l.p.	acquired	-	-	424,716	-
Apr 12, 2024	cr group l.p.	acquired	-	-	682,036	-
Apr 12, 2024	cr group l.p.	acquired	-	-	136,409	-
Feb 24, 2024	sprague john m	acquired	-	-	29.00	chief financial officer
Feb 24, 2024	sperzel john j iii	acquired	-	-	67.00	see remarks
Feb 24, 2024	gibbs michael terrence	acquired	-	-	29.00	general counsel
Feb 20, 2024	giffin brett a.	acquired	-	-	13.00	chief commercial officer
Feb 20, 2024	gibbs michael terrence	acquired	-	-	40.00	general counsel

Which funds bought or sold TTOO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	-30.00	27.00	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	sold off	-100	-207	-	-%
Apr 11, 2024	Signature Resources Capital Management, LLC	unchanged	-	-	565	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-1,000	1,000	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	286,736	286,736	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-1,299,370	-	-%
Feb 26, 2024	Virtu Financial LLC	new	-	63,000	63,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	129,000	129,000	0.01%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-570,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	96,741	96,741	-%

Are Funds Buying or Selling TTOO?

Are funds buying TTOO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TTOO

No. of Funds

Unveiling T2 Biosystems Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 19, 2024	cr group l.p.	46.68%	4,104,838	SC 13D
Mar 11, 2024	safier jacob	7.1%	350,000	SC 13G
Mar 11, 2024	new dimensions trading	7.1%	350,000	SC 13G
Feb 13, 2024	lind global fund ii lp	0.5%	20,370	SC 13G/A
Jul 31, 2023	gsa capital partners llp	1.5%	4,599,059	SC 13G
Jul 13, 2023	cr group l.p.	19.9%	72,503,592	SC 13G
Jun 30, 2023	gsa capital partners llp	15.2%	3,799,487	SC 13G
Jun 23, 2023	carrick jason	8%	2e+06	SC 13G
Jun 22, 2023	markey john	0%	0	SC 13G
Jun 21, 2023	gsa capital partners llp	10.7%	24,887,722	SC 13G

Recent SEC filings of T2 Biosystems Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	S-1	Initial Public Offering
Apr 19, 2024	SC 13D	13D - Major Acquisition
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	4	Insider Trading
Apr 12, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 20, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to T2 Biosystems Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	1.02%	7.91%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.67%	2.31%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.56%	5.45%	32.59	5.98	-2.81%	-6.58%
DGX	15.2B	9.3B	6.43%	-6.08%	17.84	1.65	-6.38%	-9.73%
CRL	12.3B	4.1B	-9.86%	27.62%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-1.17%	90.89%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	-0.82%	-0.49%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	0.12%	80.51%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-18.50%	-26.31%	1.7K	2.89	28.93%	111.61%
GH	2.2B	563.9M	5.66%	-15.62%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	413.2M	280.3M	-17.90%	-0.25%	-2.17	1.47	-12.89%	-148.37%
ACRS	83.0M	31.2M	0.86%	-86.93%	-0.94	2.66	5.03%	-1.81%
AWH	42.0M	9.2M	-4.49%	-35.24%	-2.51	4.58	11.85%	44.12%
APDN	4.1M	9.0M	-50.00%	-75.76%	-0.56	0.45	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

T2 Biosystems Inc News

Latest updates

T2 Biosystems Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	14.1%	1,679	1,472	1,964	2,078	5,483	3,677	5,911	7,234	6,980	7,428	6,694	6,956	7,788	5,245	2,552	2,545	3,069	1,677	1,804	1,785	1,792
Costs and Expenses	-27.1%	10,998	15,079	15,015	15,765	15,003	19,477	20,930	22,091	17,259	19,640	17,474	16,658	16,108	15,881	11,391	16,106	15,436	14,023	15,590	15,344	15,386
S&GA Expenses	-12.1%	5,255	5,980	6,296	7,299	6,554	7,017	7,824	9,230	6,544	8,536	7,244	6,203	4,868	5,266	5,305	6,655	7,546	5,981	6,722	7,055	6,458
R&D Expenses	19.0%	3,169	2,663	3,850	4,471	4,719	6,375	8,025	6,656	5,353	6,384	5,399	4,665	3,764	3,782	3,786	4,780	4,279	4,098	4,048	3,901	3,297
Interest Expenses	-100.0%	-	1,119	1,541	1,522	1,528	1,560	1,346	1,650	2,369	1,919	1,881	1,013	1,610	647	1,844	1,417	3,914	1,168	1,136	1,131	927
Net Income	33.0%	-10,340	-15,425	-6,347	-17,965	-10,099	-17,375	-18,034	-16,495	-12,144	-13,962	-12,475	-10,660	-9,909	-11,255	-10,685	-14,949	-14,041	-14,171	-15,647	-15,147	-15,149
Net Income Margin	-53.6%	-6.96*	-4.53*	-3.92*	-3.70*	-2.78*	-2.69*	-2.20*	-1.94*	-1.75*	-1.63*	-1.66*	-1.89*	-2.58*	-3.80*	-	-	-	-	-	-	-
Free Cashflow	29.6%	-9,442	-13,406	-12,420	-13,060	-10,365	-16,029	-10,104	-14,470	-10,041	-9,685	-10,703	-8,905	-9,129	-6,532	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-19.6%	35.00	43.00	37.00	33.00	34.00	44.00	40.00	49.00	61.00	70.00	79.00	70.00	79.00	78.00	54.00	51.00	28.00	34.00	45.00	56.00	64.00
Current Assets	-23.4%	25.00	33.00	24.00	19.00	19.00	29.00	25.00	34.00	44.00	54.00	64.00	45.00	54.00	51.00	47.00	44.00	19.00	24.00	33.00	44.00	57.00
Cash Equivalents	-35.5%	16.00	24.00	16.00	10.00	10.00	20.00	13.00	9.00	22.00	22.00	33.00	11.00	17.00	19.00	27.00	36.00	11.00	16.00	28.00	37.00	51.00
Inventory	12.6%	5.00	4.00	4.00	5.00	4.00	4.00	6.00	5.00	4.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00
Net PPE	-18.8%	2.00	2.00	5.00	5.00	5.00	5.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	6.00	6.00	7.00	7.00	7.00
Liabilities	0.5%	63.00	63.00	74.00	83.00	74.00	-	-	-	73.00	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	1.3%	56.00	55.00	66.00	18.00	10.00	11.00	13.00	13.00	12.00	11.00	9.00	10.00	10.00	10.00	8.00	58.00	61.00	58.00	58.00	54.00	52.00
Shareholder's Equity	-	-	-	-	-	-	-	-	-	-	-	9.00	-	9.00	18.00	-	-	-	-	-	-	11.00
Retained Earnings	-1.8%	-584	-573	-558	-552	-534	-524	-506	-488	-472	-460	-446	-433	-422	-413	-401	-391	-376	-362	-347	-332	-317
Additional Paid-In Capital	0.3%	556	555	522	502	495	492	469	463	459	457	455	433	432	431	397	383	342	336	332	331	329
Shares Outstanding	3.6%	4.00	4.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	31.00	-	-	-	189	-	-	-	148	-	-	-	64.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	29.7%	-9,416	-13,393	-12,387	-12,940	-10,329	-15,903	-9,956	-14,441	-9,842	-9,727	-10,597	-8,708	-8,750	-6,234	-13,491	-14,740	-10,119	-13,535	-8,840	-12,867	-9,688
Share Based Compensation	-17.0%	728	877	913	1,833	1,035	1,372	1,534	2,552	1,473	2,466	1,843	1,308	904	855	994	1,160	983	1,165	1,277	2,033	2,410
Cashflow From Investing	-100.0%	-26.00	-13.00	-33.00	-120	-36.00	-126	9,850	-29.00	9,801	42.00	12,395	2,553	6,372	-33,263	-9,303	-67.00	-26.00	-291	-250	-194	357
Cashflow From Financing	-96.2%	812	21,641	18,387	11,848	748	23,183	3,921	1,202	239	24.00	20,219	53.00	112	32,398	13,000	40,097	4,965	1,617	112	-344	-89.00

TTOO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 7,193	$ 22,305
Costs and expenses:
Cost of product revenue		21,010
Research and development	14,153	25,715
Selling, general and administrative	24,830	30,625
Impairment of property and equipment	2,511	151
Total costs and expenses	56,857	77,501
Loss from operations	(49,664)	(55,196)
Other income (expense):
Interest expense to related party	(5,343)	(6,084)
Change in fair value of derivative related to Term Loan with related party	(466)	(1,088)
Change in fair value of warrant liabilities	5,891	326
Other, net	(495)	39
Total other income (expense)	(413)	(6,807)
Net loss	(50,077)	(62,003)
Deemed dividend on Series A Redeemable Convertible Preferred Stock		(330)
Net loss attributable to common stockholders	$ (50,077)	$ (62,333)
Net loss per share - basic	$ (19.19)	$ (1,222.14)
Net loss per share - diluted	$ (19.19)	$ (1,222.14)
Weighted-average number of common shares used in computing net loss per share - basic	2,609,984	51,003
Weighted-average number of common shares used in computing net loss per share - diluted	2,609,984	51,003
Other comprehensive loss:
Net Income (Loss)	$ (50,077)	$ (62,003)
Net unrealized gain on marketable securities arising during the period		2
Net realized gain on marketable securities included in net loss		2
Total other comprehensive income, net of taxes		4
Comprehensive loss	(50,077)	(61,999)
Product [Member]
Revenue:
Total revenue	6,770	11,259
Costs and expenses:
Cost of product revenue	15,363	21,010
Contribution [Member]
Revenue:
Total revenue	$ 423	$ 11,046

TTOO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,689	$ 10,329
Accounts receivable, net	1,420	2,163
Inventories	4,819	4,285
Prepaid expenses and other current assets	3,261	2,582
Total current assets	25,189	19,359
Property and equipment, net	1,658	4,533
Operating lease right-of-use assets	7,395	8,741
Restricted cash	551	1,551
Other assets	4	143
Total assets	34,797	34,327
Current liabilities:
Accounts payable	1,527	1,296
Accrued expenses and other current liabilities	4,905	7,269
Operating lease liability	1,616	1,352
Derivative liability related to Term Loan	1,600
Warrant liabilities	235	39
Deferred revenue	224	172
Total current liabilities	56,152	10,128
Operating lease liabilities, net of current portion	6,598	8,214
Deferred revenue, net of current portion	83	52
Derivative liability related to Term Loan		1,100
Total liabilities	62,833	73,982
Commitments and contingencies (see Note 14)
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized: Series B Convertible Preferred Stock, 93,297 shares designated on December 31, 2023, 93,297 and 0 shares issued and outstanding to related party on December 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 400,000,000 shares authorized; 4,058,381 and 77,165 shares issued and outstanding on December 31, 2023 and December 31, 2022, respectively	4	0
Additional paid-in capital	556,256	494,564
Accumulated deficit	(584,296)	(534,219)
Total stockholders' deficit	(28,036)	(39,655)	$ (12,903)
Total liabilities and stockholders' deficit	34,797	34,327
Related Party [Member]
Current liabilities:
Notes payable	41,284
Accrued final payment fee on Term Loan	4,807
Derivative liability related to Term Loan	$ 1,554
Notes payable		49,651
Derivative liability related to Term Loan		1,088
Accrued final payment fee on Term Loan		$ 4,849

About T2 Biosystems Inc

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

CEO	Mr. John J. Sperzel III, B.Sc.
WEBSITE	t2biosystems.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	158

T2 Biosystems Inc Frequently Asked Questions

What is the ticker symbol for T2 Biosystems Inc? What does TTOO stand for in stocks?

TTOO is the stock ticker symbol of T2 Biosystems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of T2 Biosystems Inc (TTOO)?

As of Wed Apr 24 2024, market cap of T2 Biosystems Inc is 15.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTOO stock?

You can check TTOO's fair value in chart for subscribers.

What is the fair value of TTOO stock?

You can check TTOO's fair value in chart for subscribers. The fair value of T2 Biosystems Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of T2 Biosystems Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TTOO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is T2 Biosystems Inc a good stock to buy?

The fair value guage provides a quick view whether TTOO is over valued or under valued. Whether T2 Biosystems Inc is cheap or expensive depends on the assumptions which impact T2 Biosystems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTOO.

What is T2 Biosystems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, TTOO's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 2.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTOO PE ratio will change depending on the future growth rate expectations of investors.